ANTX - AN2 Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANTX is currently covered by 1 analysts with an average price target of $9. This is a potential upside of $3.54 (50.5%) from yesterday's end of day stock price of $5.98.

AN2 Therapeutics's activity chart (see below) currently has 15 price targets and 19 ratings on display. The stock rating distribution of ANTX is 100% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 68.25% with an average time for these price targets to be met of 266.29 days.

Highest price target for ANTX is $9, Lowest price target is $9, average price target is $9.

Most recent stock forecast was given by from LEERINK on 14-May-2026. First documented stock forecast 01-May-2019.

Best performing analysts who are covering ANTX - AN2 Therapeutics:

Kevin Degeeter Roy Buchanan Joseph Schwartz Liisa Bayko

Currently out of the existing stock ratings of ANTX, 1 are a HOLD (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 14-May-2026

$9

$3.8 (73.08%)

$1

3 months 25 days ago
(14-May-2026)

1/3 (33.33%)

$4.36 (93.97%)

7

1.39

Buy Since 04-Jan-2024

$2

$-3.2 (-61.54%)

$5

1 years 4 months 3 days ago
(05-May-2025)

8/9 (88.89%)

$0.8 (66.67%)

405

6.49

Hold Since 16-May-2024

$2

$-3.2 (-61.54%)

$2

2 years 30 days ago
(09-Aug-2024)

2/3 (66.67%)

$0.97 (94.17%)

295

Buy Since 01-May-2019

$22

$19.03 (640.74%)

$22

4 years 1 months 21 days ago
(18-Jul-2022)

3/3 (100%)

$12.54 (132.56%)

450

Show more analysts

Please expand the browser size to see the chart

What is ANTX (AN2 Therapeutics) average time for price targets to be met?

On average it took 266 days for the stock forecasts to be reached, with an average price target met ratio of 68.25%.

Which analyst most recently updated their price target on ANTX (AN2 Therapeutics)?

Which analyst has the most public recommendations on ANTX (AN2 Therapeutics)?

has 0 price targets and 0 ratings on ANTX

Which analyst is the currently most bullish on ANTX (AN2 Therapeutics)?

Kevin Degeeter with the highest potential upside of $19.03

Which analyst is the currently most reserved on ANTX (AN2 Therapeutics)?

Liisa Bayko with the lowest potential downside of -$3.89

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?